NephTech Pte Ltd
NephTech is a medical technology company dedicated to provide patients and dialysis centres an evidence-based approach to vascular access surveillance and management.
Among other innovations, the company is developing an economically feasible and revolutionary vascular access surveillance technology for kidney disease patients to:
1) leapfrog quality of care, and
2) reduce cost inefficiencies, through early prediction of vascular complications.
This, NephTech strongly believes, will address a vital unmet need to reduce the heavy financial expenditures in the hemodialysis space within developing countries.
Our business is in the data analytics of blood vessel stenosis (blockages) and being able to identify the severity of these blockages. At this moment, we are working on building a database of signals and clinical conditions that lead to these blockages.
Through creating a diagnostic system which is able to detect blockages on patients' blood vessels, we are able to sell this system to dialysis centres. The system is unable to distinguish when to escalate the severity of blockages to the hospital.
Each time the blockages are detected too late, the patients have to be admitted to the Emergency department and spend at least 6 to 10 times the original treatment, should it be conducted in an outpatient setting.
This brings our addressable market to $1.2B each year.
73 Ayer Rajah Crescent,
The Founder - Toh Yanling
Yanling co-founded NephTech, and is Chief Executive Officer (CEO) to a homegrown MedTech start-up developing cost-saving innovations for kidney disease patients. Through artificial intelligence, the technology is designed to integrate into dialysis centres, home devices, healthcare systems, to improve the quality of patient care in detecting vascular complications.
Her experience in commercialization of medical technology began as a public servant in A*STAR in the office overseeing MedTech industry development in Singapore, coordinating programmes such as CIMIT-A*STAR Collaboration and projects implementing Boston technology in multiple national hospitals.
Her everyday interactions with committed thought-leaders in patient care, engineering expertise and scientific business inspired her to plunge herself into a spin-off company from A*STAR’s Singapore-Stanford Biodesign office.
Subsequently, NephTech was founded, where the team believes in making a difference to patients’ lives through listening to customer voices to develop user-centric solutions - for the patients, by the patients.
She is trained in Mechanical Engineering, Commercial Law and Tech Transfer and certified with the inaugural cohort under the NUS-RAPS Medical Device Regulatory Affairs Programme from the National University of Singapore. She has produced and contributed to 3 patents and 1 research paper under the A*STAR-CIMIT Commercialization Project.
In her free time, Yanling enjoys outdoor activities such as hiking and water sports. She lives by the quote from Winston Churchill: “We make a living with what we get, but make a life with what we give”.
In her course of education and career, she has contributed to patients from developing countries; suffering from infectious diseases, cancer, muscular dystrophy, end stage renal disease and neurodegenerative diseases.